DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/nthl8b/n8gp_hemophilia) has announced the addition of the "N8-GP (Hemophilia A and B) - Forecast and Market Analysis to 2022" report to their offering.
The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood.
However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.
Novo Nordisk's long-lasting recombinant FVIII replacement therapy is currently in Phase III development. N8-GP is a pegylated version of Novoeight, Novo's FVIII replacement therapy that received FDA approval in October 2013. On April 26, 2012, N8-GP was awarded EMA orphan status (EU/3/12/995).
- Overview of Hemophilia A and B, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on N8-GP including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for N8-GP for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Argentina and China.
Key Topics Covered:
List of Tables
List of Figures
Opportunity and Unmet Need
For more information visit http://www.researchandmarkets.com/research/nthl8b/n8gp_hemophilia
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.